Recommendations | Pharmaceutical Strategy for Europe
The EU must ensure access to affordable and quality medicines in Europe whilst guaranteeing everyone’s right to a healthy and sustainable environment. Human medicine is not an ordinary commodity - public interest and public health should prevail as leading priorities when regulating the pharmaceutical sector.
Ahead of a stakeholders’ workshop with DG SANTE on 14-15 July, leading civil society organisations outline that it is imperative that the European Commission’s new Pharmaceutical Strategy for Europe looks beyond just profit and innovation and takes an holistic approach to safeguarding our health and
the health of our environment.